Clarient Reschedules Fourth Quarter and Year-End 2008 Financial Results Release To Wednesday, March 11th; Conference Call and We
2009年3月4日 - 10:30PM
PRニュース・ワイアー (英語)
ALISO VIEJO, Calif., March 4 /PRNewswire-FirstCall/ -- Clarient,
Inc. (NASDAQ:CLRT), a premier technology and services resource for
pathologists, oncologists and the pharmaceutical industry, today
announced that it has rescheduled the release of its financial
results for the fourth quarter and year-ended December 31, 2008 to
Wednesday, March 11th in order to complete its year end audit and
to more closely coincide with the filing of its Form 10-K for the
year ended December 31, 2008. Date: Wednesday, March 11, 2009 Start
Time: 5:00 pm EDT Call-in Number: 1-800-762-8779 (International)
480-248-5081 Conference ID Number: 3992520 Webcast:
http://www.clarientinc.com/investor Web Replay: For those unable to
participate during the live broadcast, the webcast replay will be
archived at http://www.clarientinc.com/investor shortly after the
call and will be available for one year. Speakers: Ron Andrews,
Vice Chairman and CEO; Dr. Mike Pellini, President and COO; Ray
Land, CFO Format: Discussion of fourth quarter and year-end 2008
financial results followed by Q&A About Clarient Clarient
combines innovative technologies with world-class expertise to
assess and characterize cancer. Clarient's mission is to provide
the services, resources and critical information to improve the
quality and reduce the cost of patient care as well as accelerating
the drug development process. The Company's principal customers
include pathologists, oncologists, hospitals and biopharmaceutical
companies. The rise of individualized medicine as the new direction
in oncology has created the need for a centralized resource
providing leading diagnostic technologies such as flow cytometry
and molecular testing. Clarient is that resource, having created a
state-of-the-art commercial cancer laboratory providing the most
advanced oncology testing and drug development services available
both onsite and over the web. Clarient is a Safeguard Scientifics,
Inc. partner company. http://www.clarientinc.com/ About Safeguard
Scientifics Founded in 1953 and based in Wayne, PA, Safeguard
Scientifics, Inc. (NYSE:SFE) provides growth capital for
entrepreneurial and innovative technology and life sciences
companies. Safeguard targets technology companies in Software as a
Service (SaaS) / Internet-based Businesses, Technology-Enabled
Services and Vertical Software Solutions, and life sciences
companies in Molecular and Point-of-Care Diagnostics, Medical
Devices and Specialty Pharmaceuticals with capital requirements
between $5 and $50 million. Safeguard participates in expansion
financings, corporate spin-outs, management buyouts,
recapitalizations, industry consolidations and early-stage
financings. http://www.safeguard.com/ CONTACT: Allen & Caron
Inc. Matt Clawson 949.474.4300 DATASOURCE: Clarient, Inc. CONTACT:
Matt Clawson of Allen & Caron Inc., +1-949-474-4300, Web Site:
http://www.clarientinc.com/
Copyright
Clarient, Inc. (MM) (NASDAQ:CLRT)
過去 株価チャート
から 6 2024 まで 7 2024
Clarient, Inc. (MM) (NASDAQ:CLRT)
過去 株価チャート
から 7 2023 まで 7 2024
Real-Time news about Clarient, Inc. (MM) (ナスダック市場): 0 recent articles
その他のClarient (MM)ニュース記事